Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated June 21, 2021, serves as a partial correction to the Notice of Convocation for the 145th Ordinary General Meeting of Shareholders. The document addresses specific inaccuracies regarding executive titles found in the Reference Document and Business Report associated with the meeting.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is administrative in nature and contains no financial performance data.
Material Changes
The material change reported is a correction to the title of Mr. Christophe Weber, President and Representative Director of the Company. In the documents for the General Meeting, his concurrent title at Takeda Pharmaceuticals U.S.A., Inc. was incorrectly listed as "Executive Chairman." The corrected title is "Head of Global Business."
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. The document is limited strictly to the correction of the executive title mentioned above.
Key Facts for Investors
- The filing corrects the title of Mr. Christophe Weber at Takeda Pharmaceuticals U.S.A., Inc. from "Executive Chairman" to "Head of Global Business."
- This correction applies to the Third Proposal (page 11), Fifth Proposal (page 27) of the Reference Document, and Section 3.(1) (page 68) of the Business Report.
- No financial results or strategic updates are included in this specific filing.